* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of 円22,291 Mil mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Total Current Liabilities of 円22,291 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ASKA Pharmaceutical Holdings Co and its competitors.
Is ASKA Pharmaceutical Holdings Co's Total Current Liabilities too high?
ASKA Pharmaceutical Holdings Co's current Total Current Liabilities is 円22,291 Mil. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Total Current Liabilities compare to ZTS and UTHR?
ASKA Pharmaceutical Holdings Co's Total Current Liabilities of 円22,291 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for ASKA Pharmaceutical Holdings Co and its competitors. ASKA Pharmaceutical Holdings Co's current Total Current Liabilities is 円22,291 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,400.87, compared to a current price of 円2,259.00 — trading 5.9% below its estimated fair value. The current Total Current Liabilities is 円22,291 Mil. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Total Current Liabilities is 円22,291 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,259.00 is trading 5.9% below its estimated GF Value™ of 円2,400.87.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.
Key valuation signals for TSE:4886:
Total Current Liabilities: 円22,291 Mil
GF Value™: 円2,400.87 vs. price of 円2,259.00 (5.9% below fair value)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Business Description
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
62GF Score
Get the complete analysis for TSE:4886
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
